好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

‘Amphiphysin-like’ IgGs Targeting Novel Synaptic Vesicle Trafficking Autoantigens
Autoimmune Neurology
P1 - Poster Session 1 (11:45 AM-12:45 PM)
8-002

To report 4 novel autoantibodies (resembling amphiphysin-IgG on murine brain tissue immunofluorescence assay [TIFA]) targeting antigens critical to neural synaptic vesicular trafficking.

Amphiphysin regulates synaptic vesicle endocytic recycling and is a target of paraneoplastic neurological autoimmunity (stiff-person syndrome or encephalomyeloneuropathies associated with breast adenocarcinoma and small cell carcinoma). Synaptic autoantibodies resembling amphiphysin-IgG are routinely encountered by TIFA in the Mayo Clinic Neuroimmunology Laboratory but have remained uncharacterized. 

October 2022-September 2023, 258 patient specimens (133 serums; 125 CSFs) meeting criteria for unclassified neural-restricted synaptic antibodies by TIFA were screened using protein microarray and phage-display immunoprecipitation sequencing (PhIP-Seq). Top-ranking candidate neural antigens were validated by dual-staining confocal microscopy, and ≥1 protein-specific assay (recombinant-protein western blot [all antigens] and cell-based assay [antigens #1, SNAP91; and #4, SYT3]). Clinical information was reviewed.

Four novel autoantibodies resembling amphiphysin-IgG by TIFA (but amphiphysin blot negative) that target other proteins critical for neuronal synaptic vesicle release or endocytosis were identified and validated in 9 patients: antigen #1 (SNAP91), 3 patients; antigen #2 (SNAP25), 3 patients; antigen #3 (SYNJ1), 1 patient; antigen #4 (SYT3), 2 patients. Five patients were female; median age, 56 years (range, 11-68). Clinical syndromes were: encephalitis: 2; brainstem encephalitis, 2; movement disorder, 2 (chorea, 1; PERM, 1); encephalomyelitis, myelitis, and myeloneuropathy, 1 each. Inflammatory CSF findings were present in all 3 tested (pleocytosis [1], elevated IgG index or synthesis rate [2], CSF-exclusive oligoclonal bands [1]). MRI revealed inflammatory-appearing T2 hyperintensities in 3/8 patients (cerebrum [2]; brainstem [1]; spinal cord [1, longitudinally extensive [MOG/AQP4 antibody negative]) and cerebellar atrophy, 1. One patient had known paraneoplastic cause (lung adenocarcinoma). Outcome data were available for 6 patients (clinical improvement/stability with immunotherapy [3]; clinical progression [3] including death [2], all untreated).

Antigens of the neural synaptic vesicular trafficking pathway, beyond amphiphysin, are targets in autoimmune neurological disease.

Authors/Disclosures
Michael Gilligan, MBBS
PRESENTER
Dr. Gilligan has nothing to disclose.
John R. Mills, MD, PhD (Mayo Clinic) The institution of Dr. Mills has received research support from Werfen Diagnostics. Dr. Mills has received intellectual property interests from a discovery or technology relating to health care.
Paulina Vargas Ms. Vargas has nothing to disclose.
Naveen K. Paramasivan, MD (Flat B2, AKB SPRINGS) Dr. Paramasivan has nothing to disclose.
Connie Lesnick (Mayo Clinic) Connie Lesnick has nothing to disclose.
Eati Basal Eati Basal has nothing to disclose.
Reghann LaFrance-Corey Miss LaFrance-Corey has nothing to disclose.
Surendra Dasari Surendra Dasari has nothing to disclose.
Anastasia Zekeridou, MD, PhD, FAAN (Neuroimmunology Laboratory, Mayo Clinic) The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.
Andrew McKeon, MD (Mayo Clinic) The institution of Dr. McKeon has received research support from National Institutes of Health. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received publishing royalties from a publication relating to health care.